Series D Surge: Star Therapeutics $125M Sales Trigger

🚀 Battle Card: Star Therapeutics

• Adam Rosenthal, Ph.D., Founder &amp; CEO 📧 <adam@star-therapeutics.com>

• Oversubscribed Series D funding signals strong investor confidence in antibody platforms, making this Star Therapeutics sales trigger your opener for R&amp;D scale conversations. → [Source](https://vcnewsdaily.com/star-therapeutics/venture-capital-funding/lzfxwpyvjx)

• Streamlining antibody R&amp;D workflows

• Scaling data analysis for clinical-stage development

• Primary: Integrated Lab Information Management System → Accelerate candidate discovery cycles

• Expansion: AI-driven Biostatistics Analytics → Enhance trial insights and decision speed

• HQ: South San Francisco, CA

• Employees: ≈ 150

• Rev: ≈ $20 M

• Website: [star-therapeutics.com](https://star-therapeutics.com/)

🤼 Competitive Intel

• GenScript — Discovery platforms
• Unique edge: End-to-end antibody engineering
• Evaluated by Dir. R&amp;D for candidate generation

• WuXi Biologics — CDMO services
• Unique edge: Large-scale biologics manufacturing
• Evaluated by VP Ops for scale-up flexibility

• Benchling — LIMS &amp; bioinformatics
• Unique edge: Collaborative R&amp;D notebook and data management
• Evaluated by CSO for data reporting

• LabVantage — LIMS
• Unique edge: Comprehensive lab management
• Evaluated by Lab Manager for compliance

• Veeva Systems — Clinical data management
• Unique edge: Cloud-based CTMS &amp; eTMF
• Evaluated by Clinical Ops for trial oversight

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑Integrated LIMS to accelerate candidate discovery cycles❑
PROOF_METRIC  = ❑≈ TBD❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Adam
COMPANY     = Star Therapeutics
DEPT        = R&D
SIZE        = 150
BOTTLENECK  = data analysis bottlenecks for clinical development
EVENT       = raises $125M Series D
DETAIL      = oversubscribed Series D financing
PAIN        = streamlining antibody R&D workflows
SRC         = https://vcnewsdaily.com/star-therapeutics/venture-capital-funding/lzfxwpyvjx
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 150
REV_EST     = ≈ $20 M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 150-person R&D

Adam—noticed your R&D team is ≈ 150.

That’s when data analysis bottlenecks for clinical development slows growth.

We helped ≈ TBD fix this with Integrated LIMS to accelerate candidate discovery cycles.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about oversubscribed Series D financing — streamlining antibody R&D workflows.  
Integrated LIMS to accelerate candidate discovery cycles. ≈ TBD.  
Quick chat?